Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer

Background Elpamotide is an HLA-A*24:02-restricted epitope peptide of vascular endothelial growth factor receptor 2 (VEGFR-2) and induces cytotoxic T lymphocytes (CTLs) against VEGFR-2/KDR. Given the high expression of VEGFR-2 in biliary tract cancer, combination chemoimmunotherapy with elpamotide a...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Invest New Drugs
Auteurs principaux: Matsuyama, Masato, Ishii, H., Furuse, J., Ohkawa, S., Maguchi, H., Mizuno, N., Yamaguchi, T., Ioka, T., Ajiki, T., Ikeda, M., Hakamada, K., Yamamoto, M., Yamaue, H., Eguchi, K., Ichikawa, W., Miyazaki, M., Ohashi, Y., Sasaki, Y.
Format: Artigo
Langue:Inglês
Publié: Springer US 2014
Sujets:
Phase II Studies
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4387249/
https://ncbi.nlm.nih.gov/pubmed/25502982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0197-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires